- MACROCYCLIC SERINE PROTEASE INHIBITORS
-
Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula Ia or Ib, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.
- -
-
Paragraph 0224
(2017/05/31)
-
- Advanced asymmetric synthesis of (1R,2S)-1-amino-2-vinylcyclopropanecarboxylic acid by alkylation/cyclization of newly designed axially chiral Ni(II) complex of glycine Schiff base
-
Asymmetric synthesis of (1R,2S)-1-amino-2-vinylcyclopropanecarboxylic acid (vinyl-ACCA) is in extremely high demand due to the pharmaceutical importance of this tailor-made, sterically constrained α-amino acid. Here we report the development of an advanced procedure for preparation of the target amino acid via two-step SN2 and SN2′ alkylation of novel axially chiral nucleophilic glycine equivalent. Excellent yields and diastereoselectivity coupled with reliable and easy scalability render this method of immediate use for practical synthesis of (1R,2S)-vinyl-ACCA.
- Kawashima, Aki,Shu, Shuangjie,Takeda, Ryosuke,Kawamura, Akie,Sato, Tatsunori,Moriwaki, Hiroki,Wang, Jiang,Izawa, Kunisuke,Acea, Jos Luis,Soloshonok, Vadim A.,Liu, Hong
-
p. 973 - 986
(2016/04/04)
-
- METHOD FOR SYNTHESIZING OPTICALLY ACTIVE a-AMINO ACID USING CHIRAL METAL COMPLEX COMPRISING AXIALLY CHIRAL N-(2-ACYLARYL)-2-[5,7-DIHYDRO-6H-DIBENZO[c,e]AZEPIN-6-YL] ACETAMIDE COMPOUND AND AMINO ACID
-
Objects of the present invention are to provide an industrially applicable method for producing an optically active α-amino acid in high yield and in a highly enantioselective manner, to provide a simple production method of an optically active α,α-disubstituted α-amino acid, and to provide an intermediate useful for the above production methods of an optically active α-amino acid and an optically active α,α-disubstituted α-amino acid. The present invention provides a production method of an optically active α-amino acid or a salt thereof, the production method comprising introducing a substituent into the α carbon in the α-amino acid moiety of a metal complex represented by the following Formula (1): by an alkylation reaction, an aldol reaction, the Michael reaction, or the Mannich reaction, and releasing an optically pure α-amino acid enantiomer or a salt thereof by acid decomposition of the metal complex.
- -
-
Paragraph 0487-0490
(2016/05/10)
-
- Preparation method for alpha-amino acid
-
The invention provides a preparation method for an alpha-amino acid and belongs to the pharmaceutical technical field. The preparation method comprises the following steps: in the presence of an alkali, performing a reaction of a metal complex in an organic solvent to obtain a complex; and then hydrolyzing the complex and/or reacting with a protecting agent to obtain the alpha-amino acid or derivatives thereof. The method provided by the invention can simply obtain the amino acid or derivatives thereof without splitting the product, so that the yield is high, the cost is low, and industrial production is facilitated.
- -
-
Paragraph 0114; 0115; 0116; 0117; 0123
(2016/10/09)
-
- Macrocyclic compounds for suppressing replication of hepatitis C virus
-
A compound as represented by Formula (I) is provided, wherein groups are defined in the description. The compound is used as HCV protease inhibitor for treating HCV infection.
- -
-
-
- HCV NS3 protease inhibitors
-
The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
- -
-
Page/Page column 94
(2016/06/01)
-
- METHOD FOR SYNTHESIZING OPTICALLY ACTIVE α-AMINO ACID USING CHIRAL METAL COMPLEX COMPRISING AXIALLY CHIRAL N-(2-ACYLARYL)-2-[5,7-DIHYDRO-6H-DIBENZO[c,e]AZEPIN-6-YL]ACETAMIDE COMPOUND AND AMINO ACID
-
Objects of the present invention are to provide an industrially applicable method for producing an optically active ±-amino acid in high yield and in a highly enantioselective manner, to provide a simple production method of an optically active ±,±-disubstituted ±-amino acid, and to provide an intermediate useful for the above production methods of an optically active ±-amino acid and an optically active ±,±-disubstituted ±-amino acid. The present invention provides a production method of an optically active ±-amino acid or a salt thereof, the production method comprising introducing a substituent into the ± carbon in the ±-amino acid moiety of a metal complex represented by the following Formula (1): by an alkylation reaction, an aldol reaction, the Michael reaction, or the Mannich reaction, and releasing an optically pure ±-amino acid enantiomer or a salt thereof by acid decomposition of the metal complex.
- -
-
Paragraph 0842; 0844
(2016/11/17)
-
- Asymmetric synthesis of (1R,2S)-1-amino-2-vinylcyclopropanecarboxylic acid by sequential SN2-SN2′ dialkylation of (R)-N-(benzyl)proline-derived glycine Schiff base Ni(ii) complex
-
This work describes a new process for the asymmetric synthesis of (1R,2S)-1-amino-2-vinylcyclopropanecarboxylic acid of high pharmaceutical importance. The sequence of the reactions includes PTC alkylation (SN2), homogeneous SN2′ cyclization followed by disassembly of the resultant Ni(ii) complex. All reactions are conducted under operationally convenient conditions and suitably scaled up to 6 g of the starting Ni(ii) complex. This journal is
- Kawashima, Aki,Xie, Chen,Mei, Haibo,Takeda, Ryosuke,Kawamura, Akie,Sato, Tatsunori,Moriwaki, Hiroki,Izawa, Kunisuke,Han, Jianlin,Acea, Jos Luis,Soloshonok, Vadim A.
-
p. 1051 - 1058
(2015/02/02)
-
- HCV NS3 PROTEASE INHIBITORS
-
The present invention is directed to compounds, compositions and methods for treating or preventing HCV viral infections in human patients or other animal hosts.
- -
-
Page/Page column 24
(2013/07/25)
-
- HCV NS3 PROTEASE INHIBITORS
-
The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
- -
-
Page/Page column 73
(2013/06/05)
-
- NOVEL SPECIFIC HCV NS3 PROTEASE INHIBITORS
-
The present invention is directed to compounds, compositions and methods for treating or preventing viral infections, in particular, HCV in human patients or other animal hosts.
- -
-
Page/Page column 24
(2012/05/20)
-
- OPTICALLY ACTIVE VINYL-CYCLOPROPANE CARBOXYLIC ACID DERIVATIVE AND OPTICALLY ACTIVE VINYL-CYCLOPROPANE AMINO ACID DERIVATIVE MANUFACTURING METHOD
-
The objective of the present invention is to provide a method for obtaining an optically active vinylcyclopropanecarboxylic acid derivative with high yield and high optical purity using a safe material available at low cost. In addition, the objective of the present invention is to provide a method for safely-obtaining an optically active vinylcyclopropaneamino acid with high optical purity at low cost. The problems can be solved by a method for obtaining an optically active vinylcyclopropanecarboxylic acid derivative, which method contains the step of reacting a racemic vinylcyclopropanecarboxylic acid derivative with an optically active amine compound, to obtain a diastereomer salt of optically active vinylcyclopropanecarboxylic acid derivative - amine compound. In addition, it is possible to obtain a vinylcyclopropaneamino acid by deriving the vinylcyclopropaneamino acid from thus obtained diastereomer salt of optically active vinylcyclopropanecarboxylic acid derivative - amine compound.
- -
-
Page/Page column 12-13
(2011/08/04)
-
- MACROCYCLIC SERINE PROTEASE INHIBITORS USEFUL AGAINST VIRAL INFECTIONS, PARTICULARLY HCV
-
Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula (Ia) or (Ib), pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.
- -
-
Page/Page column 130
(2011/02/24)
-
- HCV PROTEASE INHIBITORS
-
This invention relates to macrocyclic compounds of formula (I) shown in the specification. These compounds can be used to treat hepatitis C virus infection.
- -
-
Page/Page column 55-59
(2011/04/18)
-
- HCV PROTEASE INHIBITORS
-
This invention relates to macrocyclic compounds shown in the specification. These compounds can be used to treat hepatitis C virus infection.
- -
-
Page/Page column 34
(2011/04/19)
-
- THERAPEUTIC ANTIVIRAL PEPTIDES
-
Disclosed herein are compounds represented by a formula: Therapeutic methods, compositions, medicaments, and dosage forms related thereto are also disclosed.
- -
-
-
- MACROCYCLIC SERINE PROTEASE INHIBITORS
-
Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula I, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof
- -
-
-
- HCV PROTEASE INHIBITORS
-
This invention relates to macrocyclic compounds of formula (I) or (II) shown in the specification. These compounds can be used to treat hepatitis C virus infection.
- -
-
Page/Page column 16-17
(2009/12/05)
-
- Hepatitis C Virus Inhibitors
-
Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
- -
-
Page/Page column 26-27
(2009/12/02)
-
- Antiviral compounds
-
The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
- -
-
Page/Page column 33-34
(2009/03/07)
-
- Inhibitors of Hepatitis C Virus
-
Macrocyclic peptides are disclosed having the general formula: wherein R3, R3′, R4, R6, R′, X, Q and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
- -
-
-
- Hepatitis C Virus Inhibitors
-
Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
- -
-
-
- MACROCYCLIC PEPTIDES AS HEPATITIS C VIRUS INHIBITORS
-
Macrocyclic peptides having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
- -
-
-
- Inhibitors of Hepatitis C Virus
-
Macrocyclic peptides are disclosed having the general formula: wherein R3, R′3, R4, R6, R′, X, Q and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
- -
-
-
- Inhibitors of Hepatitis C Virus
-
Macrocyclic peptides are disclosed having the general formula: wherein R3, R3′, R4, R6, R′, X, Q and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
- -
-
Page/Page column 21
(2008/12/04)
-
- Hepatitis C Virus Inhibitors
-
Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
- -
-
Page/Page column 33-34
(2008/06/13)
-
- MACROCYCLIC PEPTIDES AS HEPATITIS C VIRUS INHIBITORS
-
Macrocyclic peptides having the general formula (I): are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
- -
-
Page/Page column 64-65
(2008/12/05)
-
- HEPATITIS C INHIBITOR PEPTIDE ANALOGS
-
The compounds of formula I wherein R1, R2, R3 , R4 and R5 are defined herein, are useful as inhibitors of the hepatitis C virus NS3 protease The invention further relates to azalactone compounds of the formula (II) which can be reacted with an amide anion to produce the HCV NS3 protease inhibitors of formula (I)
- -
-
Page/Page column 43-44
(2010/11/25)
-
- Hepatitis C virus inhibitors
-
Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
- -
-
Page/Page column 46
(2010/11/26)
-
- Hepatitis C virus inhibitors
-
Macrocyclic peptides are disclosed having the general formula: wherein R′, R3, R3′, R4, R6, X, Q, and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
- -
-
Page/Page column 35-36
(2010/11/26)
-
- Hepatitis C virus inhibitors
-
The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which inhibit the function of the NS3 protease (also referred to herein as “serine protease”) encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS3 protease.
- -
-
Page/Page column 32-33; 44
(2008/06/13)
-
- HEPATITIS C VIRUS INHIBITORS
-
Hepatitis C virus inhibitors are disclosed having the general formula:(I) wherein R1, R2, R3, R', B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds toinhibit HCV are also disclosed.
- -
-
-
- Enantioselective synthesis of (1R,2S) and (1S,2S) dehydrocoronamic acids
-
Thanks to the successive use of two esterases with different regioselectivities and conventional organic chemistry we have synthesized (1R,2S) and (1S,2S) dehydrocoronamic acids.
- Fliche,Braun,Le Goffic
-
p. 2873 - 2876
(2007/10/02)
-